Document Detail

Intermediate and normal sized CGG repeat on the FMR1 gene does not negatively affect donor ovarian response.
MedLine Citation:
PMID:  22157911     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Fragile X syndrome is associated with low ovarian reserve and poor ovarian response. The aim of this study was to investigate whether CGG repeats on the fragile X mental retardation 1 (FMR1) gene have predictive value for ovarian response to stimulation with gonadotrophins and for clinical outcome in our oocyte donation program.
METHODS: Oocyte donor candidates were selected according to Instituto Bernabeu oocyte donation program requirements. Fragile X genetic screening was performed in 204 oocyte donors, defining 141 controls and 63 cases: 35-39 repeats (n = 34), 40-45 (n = 12) and >45 (n = 17). All the patients underwent ovarian stimulation using a GnRH antagonist protocol and received a GnRH agonist trigger. The main factors used to measure outcome were oocyte yields, days of stimulation, gonadotrophin dosages, biochemical pregnancy, ongoing pregnancy and miscarriage rates.
RESULTS: No differences between the study group and controls were reported in oocyte yields (17.5 versus 18.9) or days of stimulation (11.40 versus 9.82). The control group used significantly more gonadotrophin (2212 versus 1850 IU) than the study group. Clinical outcome was not affected by the CGG repeats on the FMR1 gene in oocyte donors.
CONCLUSIONS: No negative effect was observed for intermediate-sized CGG repeats on ovarian stimulation and clinical outcome using a non-confounding model of oocyte donation. These results disagree with previous studies performed on infertility patients. Owing to the present study, fragile X genetic screening should not be considered for prediction of response to ovarian stimulation.
B Lledo; J Guerrero; J A Ortiz; R Morales; J Ten; J Llacer; J Gimenez; R Bernabeu
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-12-07
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  27     ISSN:  1460-2350     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-16     Completed Date:  2012-05-18     Revised Date:  2012-08-13    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  609-14     Citation Subset:  IM    
IB Biotech, Avda. Albufereta, 31, 03016 Alicante, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortion, Spontaneous / genetics
Dose-Response Relationship, Drug
Fragile X Mental Retardation Protein / chemistry,  genetics*
Gonadotropin-Releasing Hormone / agonists,  antagonists & inhibitors
Gonadotropins / administration & dosage,  pharmacology
Hormone Antagonists / administration & dosage,  pharmacology
Infertility, Female / therapy
Medical Records
Oocyte Donation*
Ovulation / drug effects*
Ovulation Induction*
Pregnancy Maintenance
Pregnancy Rate
Retrospective Studies
Tissue Donors*
Trinucleotide Repeats*
Young Adult
Reg. No./Substance:
0/FMR1 protein, human; 0/Gonadotropins; 0/Hormone Antagonists; 139135-51-6/Fragile X Mental Retardation Protein; 33515-09-2/Gonadotropin-Releasing Hormone
Comment In:
Hum Reprod. 2012 Jul;27(7):2241-2; author reply 2242-3   [PMID:  22617125 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Five dysfunctional telomeres predict onset of senescence in human cells.
Next Document:  Prenatal stress, gestational age and secondary sex ratio: the sex-specific effects of exposure to a ...